Cagrilintide

Cagrilintide is a long-acting acylated amylin analogue studied as a research tool for probing amylin biology, a pancreatic signaling pathway that has received less attention than insulin, glucagon, and the incretins.

Analogue Design

Native amylin has a very short half-life, poor solubility, and a tendency to aggregate into amyloid fibrils. Cagrilintide was designed with amino acid substitutions to reduce aggregation and with fatty-acid acylation to promote reversible albumin binding, extending its circulating half-life in laboratory models.

Position in Combination Research

Because amylin and incretin pathways are mechanistically distinct, cagrilintide is frequently studied alongside GLP-1 receptor agonists to examine whether combined pathway activation differs from single-pathway activation. This material is supplied strictly as a research chemical for laboratory use.

Refer to the cited literature for research concerning this material's molecular characteristics and experimental targets.

Published nonclinical literature relevant to this material's molecular targets and experimental models is listed below for independent review. Findings involving other preparations or experimental systems should not be attributed to this research material.

This material is supplied solely for in vitro and other nonclinical laboratory research. It is not for human or veterinary use, consumption, administration, therapeutic use, or diagnostic use.

Laboratory Handling

Handle only in an appropriately equipped laboratory using applicable institutional procedures, personal protective equipment, and the storage conditions shown for the material. The purchaser is responsible for study design, handling controls, disposal, and regulatory compliance.

Research Limitations

Published observations involving other preparations, experimental systems, or study populations do not establish the identity, performance, or suitability of this research material for any particular experiment.